Dichloroisoprenaline
From Self-sufficiency
| Dichloroisoprenaline | |
|---|---|
| File:Dichloroisoprenaline.svg | |
| Dichloroisoprenaline | |
| 1-(3,4-Dichlorophenyl)-2-[(propan-2-yl)amino]ethan-1-ol | |
| Other names 1-(3,4-Dichlorophenyl)-2-(isopropylamino)ethanol Dichlorisoproterenol | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 59-61-0 |
| PubChem | 443400 (1R)  , 6951395 (1S) , 5806 ()
|
| ChemSpider | 391627 (1R) , 5324297 (1S) , 5601 ()
|
| KEGG | C11772 |
| MeSH | Dichloroisoproterenol |
| ChEBI | 144234 |
| SMILES | Script error: No such module "collapsible list". |
| InChI | Script error: No such module "collapsible list". |
| InChI key | VKMGSWIFEHZQRS-UHFFFAOYSA-N |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C11H15Cl2NO |
| Molar mass | 248.15 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Dichloroisoprenaline (DCI), also known as dichlorosisoproterenol, was the first beta blocker ever to be developed. It is non-selective for the β1-adrenergic and β2-adrenergic receptors. DCI has low potency and acts as a partial agonist/antagonist at these receptors.
Although DCI was of no clinical value itself, further developments from DCI eventually led to the development of the clinical candidate pronethalol (withdrawn due to carcinogenicity) and subsequently propranolol (the first clinically-successful beta blocker).
Dichloroisoprenaline is a racemic mixture of enantiomers.
File:(±)-Dichlorosisoproterenol Enantiomers Structural Formulae.png
The two enantiomers of dichloroisoprenaline
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />| 32px | This chemistry-related article is a stub. You can help ssf by expanding it. |
-Dichlorosisoproterenol_Enantiomers_Structural_Formulae.png){kind=link}
